{"groups":[{"description":"Nivolumab 240 mg infusion on Day 1 and every two weeks during cycles 1 and 2 for a total of 6 doses. Starting from Cycle 3 Day 1 participants received Nivolumab 480 mg infusion every 4 weeks.","id":"FG000","title":"Arm A - Nivolumab Monotherapy"},{"description":"Nivolumab 240 mg infusion followed by Ipilimumab 1 mg/kg IV on Day 1 and every three weeks during cycles 1 and 2 for a total of 4 doses. Starting from Cycle 3 Day 1, participants received Nivolumab 480 mg infusion every 4 weeks.","id":"FG001","title":"Arm B - Nivolumab + Ipilimumab"},{"description":"Participants received standard of care chemotherapy","id":"FG002","title":"Arm C - Investigator's Choice Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}],"type":"Participant no longer meets study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"6"}],"type":"Other reasons"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"353"},{"groupId":"FG001","numSubjects":"354"},{"groupId":"FG002","numSubjects":"132"}],"comment":"Randomized","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"351"},{"groupId":"FG001","numSubjects":"352"},{"groupId":"FG002","numSubjects":"115"}],"comment":"Treated","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"17"}],"type":"NOT COMPLETED"}],"title":"Pre-Treatment"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Pregnancy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Participant no longer meets study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"6"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"137"},{"groupId":"FG001","numSubjects":"82"},{"groupId":"FG002","numSubjects":"85"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"48"},{"groupId":"FG002","numSubjects":"8"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"6"}],"type":"Adverse Event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"9"}],"type":"Maximum Clinical Benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"0"}],"type":"On-going treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"351"},{"groupId":"FG001","numSubjects":"352"},{"groupId":"FG002","numSubjects":"115"}],"comment":"Treated","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"60"}],"type":"Crossover to Arm B"},{"achievements":[{"groupId":"FG000","numSubjects":"137"},{"groupId":"FG001","numSubjects":"159"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"214"},{"groupId":"FG001","numSubjects":"193"},{"groupId":"FG002","numSubjects":"115"}],"type":"NOT COMPLETED"}],"title":"Treatment"}]}